A detailed history of Jpmorgan Chase & CO transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 10,812 shares of TRDA stock, worth $209,428. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,812
Previous 10,570 2.29%
Holding current value
$209,428
Previous $150,000 14.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$13.65 - $17.86 $3,303 - $4,322
242 Added 2.29%
10,812 $172,000
Q2 2024

Aug 12, 2024

BUY
$11.85 - $16.45 $25,560 - $35,482
2,157 Added 25.64%
10,570 $150,000
Q1 2024

May 10, 2024

SELL
$11.58 - $17.0 $66,480 - $97,597
-5,741 Reduced 40.56%
8,413 $119,000
Q4 2023

Feb 12, 2024

SELL
$11.36 - $16.99 $4,850 - $7,254
-427 Reduced 2.93%
14,154 $213,000
Q3 2023

Nov 14, 2023

SELL
$13.61 - $18.01 $28,159 - $37,262
-2,069 Reduced 12.43%
14,581 $230,000
Q2 2023

Aug 11, 2023

BUY
$11.02 - $18.01 $89,372 - $146,061
8,110 Added 94.96%
16,650 $252,000
Q1 2023

May 18, 2023

BUY
$9.58 - $16.2 $80,347 - $135,869
8,387 Added 5481.7%
8,540 $123,000
Q1 2023

May 11, 2023

SELL
$9.58 - $16.2 $71,275 - $120,528
-7,440 Reduced 97.98%
153 $2,000
Q4 2022

Feb 13, 2023

BUY
$13.52 - $22.89 $102,657 - $173,803
7,593 New
7,593 $103,000
Q2 2022

Aug 11, 2022

SELL
$5.49 - $12.94 $27,087 - $63,845
-4,934 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$7.99 - $16.93 $11,505 - $24,379
1,440 Added 41.21%
4,934 $46,000
Q4 2021

Feb 10, 2022

BUY
$13.7 - $35.0 $47,867 - $122,290
3,494 New
3,494 $60,000

Others Institutions Holding TRDA

About Entrada Therapeutics, Inc.


  • Ticker TRDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,368,500
  • Market Cap $608M
  • Description
  • Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...
More about TRDA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.